Abstract: Compounds represented by general Formulae I to IV as described herein are disclosed. Further disclosed are composition utilizing the herein disclosed compounds and using the same for the treatment of glycogen storage disorders.

Abstract: Disclosed herein are devices/kits and methods for reducing, treating, preventing or eliminating post-operative adhesions in an intervention/target site within a body of a subject. The method comprises the steps of: introducing an applicator, configured for applying an anti-adhesive composition, into an intervention/target site within a body of a subject; applying the anti-adhesive composition onto the intervention/target site; and extracting the applicator from the body of the subject, wherein the method is performed during or following an interventional procedure.

Abstract: The present invention provides compositions having one or more agents capable of increasing expression of one or more endogenous tumor suppressive mi RNAs in one or more producing cells, such that the endogenous mi RNAs can affect one or more target cancer cells. Further provided are method and uses thereof for treating cancer.

Abstract: A computer-implemented method comprising: receiving a plurality of CBCT scans, each comprising a series of axial slices, wherein the CBCT scans are associated with a cohort of subjects comprising a first subgroup of subjects having each one or more maxillofacial bone lesions, and a second subgroup of subjects having no maxillofacial bone lesions; applying a feature extraction operation to extract a set of features from the axial slices in each of the CBCT scans; at a training stage, training a machine learning model on a training dataset comprising: (i) all of the extracted sets of features, and (ii) annotations indicating boundaries of bone lesions in the axial slices, to obtain a trained machine learning model configured to detect and segment a bone lesion in an axial slice from a CBCT scan.

Abstract: The invention relates to cancer immunotherapy, particularly to improved therapeutic modalities involving specifically modulating the expression and/or activity of SLAMF6 splice variants. More specifically, embodiments of the invention provide compositions and methods for cancer therapy, including adoptive T cell transfer therapies, cell vaccines and/or polypeptide- based medicaments. In various embodiments, compositions and methods providing selective augmentation of SLAMF6 variant 3 (SLAMF6var3) N expression or activity on T cells and/or tumor cells are provided.

Abstract: The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenerative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).

Abstract: A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGF? superfamily.

Abstract: The present invention relates to an heparanase-binding and heparanase-neutralizing monoclonal antibody (IgG-1 mAb A54), including its epitope (HBD-II) and mode of interaction with heparanase, pharmaceutical composition comprising same, and uses thereof e.g. for inhibiting or treating a disease or disorder associated with heparanase activity, including but not limited to cancer, inflammation, viral infection, diabetes and related complications. The present invention further provides combinatorial cancer therapies, comprising the heparanase-neutralizing mAb and an additional anti-cancer treatment such as chemotherapy or radiation.

Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.

Abstract: Disclosed are peptides that specifically bind to neutrophils and uses thereof for neutrophil-targeted delivery of drugs or diagnostic agents in medical conditions including cancer as well as infectious, inflammatory and autoimmune diseases or disorders.

Abstract: Devices and method for determining a pupil size of a subject having closed eyelids.

Abstract: The present invention relates to a device for repair of a region within an ear via a natural orifice, the device comprising a body. The body comprises a first port for visibly identifying the region to be sealed, the region being inside the ear; and a second port through which a seal can be introduced into the ear through the device. The region comprises a perforation of a tympanic membrane of the ear and the device is a speculum. The present invention also relates to method for repairing a perforation in a tympanic membrane using the same device.

Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.

Abstract: The present invention provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising use of artemisone in combination with at least one antiviral compound selected from maribavir, cidofovir, brincidofovir, valganciclovir, and letermovir, and the combination provides a synergistic anti-viral effect. The invention also provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising the use of artemisone in combination with ganciclovir, wherein the molar ratio between artemisone and ganciclovir is about 1:100 to 100:1, and the combination provides a synergistic anti-viral effect. Pharmaceutical compositions comprising artemisone and at least one of said antiviral compounds are provided as well.

Abstract: A method for influencing cerebral perfusion in a patient by modifying a volume of a volume adaptor introduced into a cerebral ventricle of the patient, the method comprising identifying a timing of a cerebral blood inflow and/or outflow in a cardiac activity of the patient, modifying a volume of the volume adaptor in synchronization to the identified timing of the cerebral blood flow, to an amount sufficient to modify an intracranial pressure in the cerebral ventricle, such that a flow of the cerebral blood flow is enhanced. In some exemplary embodiments of the invention, the inflation duration of the volume adapter is short relative to the cardiac cycle.

Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.

Abstract: The invention relates to the treatment of brain tumors, specifically to improved therapy for glioblastoma utilizing specific endocrine modulators and drug combinations. The compositions and uses thereof according to the invention employ androgen receptor (AR) inhibitors, either alone or in combination with receptor tyrosine kinase inhibitors and/or chemotherapeutic agents. According to certain advantageous embodiments, the use of the AR inhibitor enzalutamide, optionally in combination with epidermal growth factor receptor inhibitors such as erlotinib and alkylating agents such as carmustine and temozolomide, is contemplated.

Abstract: A digital droplet PCR method of analyzing the methylation status of methylation sites of a double-stranded DNA molecule which comprises at least two methylation sites per single strand of the double-stranded DNA molecule is disclosed.

Abstract: A method of generating human mature oligodendrocytes is disclosed. The method comprises contacting a cell population which comprises human pre-oligodendrocytes with an inhibitor of the MAPK/ERK pathway under conditions that allow the pre-oligodendrocytes to differentiate into mature oligodendrocytes. Use of the MAPK/ERK pathway inhibitor for treating diseases is also disclosed.

Abstract: The present invention relates to anti-microbially active micro and nanoparticles, compositions comprising same, and use thereof for inhibiting bacterial growth and biofilm formation on surfaces or devices, e.g., dental surfaces or devices. The present invention further discloses methods of making such anti-microbially active micro or nanoparticles.